The hepatitis C virus (HCV) is a significant human pathogen of global impact. Therapeutic intervention to cure infections, although improving with recent specific antivirals, still remains a challenge because of the diversity of HCV genotypes and the ability of the virus to quickly evolve resistance. An evolving list of antiviral targets is therefore necessary to help stem the global burden of HCV, and the structural characterization of key viral proteins is of significant importance to this effort.